Korro Bio Inc. (KRRO)
NASDAQ: KRROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KRRO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $167.18M
- EPS (TTM)
- -$8.89
- Dividend yield
- None
- 52-week range
- 5.20 – 17.35
- Day range
- 12.01 – 12.95
- Volume / Avg
- 123.52K / 186.03K
- Beta
- —
- Shares outstanding
- 13.73M
52-week range
KRRO stock today
Korro Bio (KRRO) closed at $12.18 on Nov 20, down 0.08% (-$0.01), versus the S&P 500's 3.70% decline. At this level, KRRO sits in the middle of its 52-week range of $5.20 to $17.35: 29.8% below the high, set on Nov 3, 2026 and 134.1% above the low. KRRO is up 52.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 93.9%.
Korro Bio has posted a net loss over the last twelve months (EPS of -$8.89), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Korro Bio
Company profileKorro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Ram Aiyar MBA, Ph.D.
- Headquarters
- Cambridge, MA
- Employees
- 58
- IPO year
- 2019
- Website
- korrobio.com
Financial highlights
Full financialsIn fiscal 2025, Korro Bio generated $6.4 million in revenue, up 181.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Korro Bio reported a net loss of $117.3 million, compared with a loss of $83.6 million a year earlier. Operating margin was -1906.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $6.39M | $2.27M | $0 | $0 | $14.07M |
| Growth | +181.46% | — | — | -100.00% | -61.96% |
| Net income | $-117.26M | $-83.58M | $-81.17M | $-58.03M | $-84.69M |
| EPS (diluted) | $-12.48 | $-9.37 | $-53.08 | $-227.42 | $-2.47 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$21.50+76.52%
- Strong buy 2
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.98 vs $-1.14
- Surprise
- +14.04%
KRRO news
All KRRO news- Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Korro to Present at the 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Korro Bio Announces Preclinical Results for KRRO-111Nasdaq
- Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
Korro Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABEOAbeona Therapeutics Inc. | 2.42 | -1.22% | $165.31M | vs KRRO |
| TRDAEntrada Therapeutics Inc. | 4.35 | -6.25% | $170.30M | vs KRRO |
| EMISEmmis Acquisition Corp. Class A | 10.36 | +0.15% | $163.36M | vs KRRO |
| SIGASIGA Technologies Inc. | 2.40 | -9.43% | $172.45M | vs KRRO |
| VOGXVogenx Inc | 11.87 | -7.30% | $176.33M | vs KRRO |
| NATRNature's Sunshine Products Inc. | 10.18 | +0.10% | $176.41M | vs KRRO |
| ORMPOramed Pharmaceuticals Inc. | 3.57 | -3.25% | $155.24M | vs KRRO |
| ADCTADC Therapeutics SA | 1.28 | -1.54% | $180.05M | vs KRRO |
Indexes, lists and sector
Korro Bio stock FAQ
What is Korro Bio's stock price today?
KRRO last traded at $12.18 as of Nov 20, 4:00 PM EST, down 0.08% on the day. Prices are delayed at least 15 minutes.
Does Korro Bio pay a dividend?
No. Korro Bio does not currently pay a regular cash dividend.
Who is Korro Bio's CEO?
Dr. Ram Aiyar MBA, Ph.D. is the chief executive officer of Korro Bio Inc., which has about 58 employees.
Has KRRO ever split its stock?
Yes. The most recent KRRO stock split was a 1-for-50 split on Nov 6, 2023.
What is the KRRO 52-week high?
The 52-week high for KRRO is $17.35 and the 52-week low is $5.20. The stock is currently 29.8% below its high.